Sanofi partners with SIRION to improve AAV capsids for gene therapy treatments
Sanofi and SIRION will combine their technology platforms to develop next-generation AAV vectors
Read More
Tag: adeno-associated virus vector
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
